profit from every $100 of sales.
$0$100
Organigram Global
$0.83-2.31% today
-48.2% in 1 year
1-year low $0.831-year high $2.11
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2021 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Organigram Global sold, what it kept, and what it did with the cash.
Sales went from CA$79.2 million in 2021 to CA$259 million in 2025, with -CA$24.8 million of profit last year.
SalesProfit
Organigram Global vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Organigram Global | No profit yet | ||
 Merck KGaA | 24.8× · Fair price | ||
 Takeda Pharmaceutical | 101.0× · Very expensive | ||
 Galderma Group | 88.6× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.1× · Expensive |
AI analysis
An AI analyst reads Organigram Global's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| 79 | 146 | 160 | 259 | |
| -28 | 32 | 48 | 90 | |
| -73 | -39 | -35 | -15 | |
| -97 | 11 | -23 | 3 | |
| -131 | -14 | -45 | -25 | |
| -2.04 | -0.19 | -0.48 | -0.19 | |
| -35.9% | 21.7% | 29.7% | 34.8% | |
| -92.0% | -26.6% | -21.7% | -5.9% | |
| -165.1% | -9.8% | -28.4% | -9.6% |
Balance sheet
| In millions of CAD | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 554 | 577 | 408 | 562 |
| Cash | 55 | 69 | 107 | 28 |
| Total debt | 6 | 3 | 4 | 9 |
| Total liabilities | 74 | 69 | 102 | 213 |
| 480 | 508 | 306 | 349 | |
| 64 | 77 | 95 | 128 | |
| -20.8% | -2.2% | -8.8% | -3.4% | |
| -27.2% | -2.8% | -14.9% | -7.1% |
Cash flow
| In millions of CAD | 2021 | 2022 | 2024 | 2025 |
|---|---|---|---|---|
| -29 | -36 | 4 | -8 | |
| 12 | 49 | 5 | 17 | |
| -41 | -85 | -1 | -25 | |
| Dividends paid | 0 | 0 | – | – |
| – | – | – | – | |
| 4 | 5 | 7 | 4 |
Valuation
- –
- 5.9×
- –
- 0.5×
- 0.6×
- –
- 55.4×
- -14.7%
- -14.8%
- 0.0%
Profitability
- 34.8%
- -5.9%
- -9.6%
- -14.9%
- -15.8%
- -26.5%
- -6.8%
- -4.8%
- -24.5%
- 2.9%
Growth
- +34.5%
- –
- −1,027.1%
- –
- +18.8%
Financial health
- 1.1×
- 0.02
- 1.6%
- –
- 2.82
- 1.30
- 0.53
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 23%of 952
Bottom 17%of 883
Top 16%of 870
Bottom 7%of 985
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.01 | -0.01 | +0.0% |
| Feb 10, 2026 | -0.02 | -0.01 | −100.0% |
| Dec 16, 2025 | -0.20 | -0.00 | −4,058.0% |
| Aug 13, 2025 | -0.03 | -0.01 | −200.0% |
| May 12, 2025 | -0.05 | -0.03 | −66.7% |
| Feb 11, 2025 | -0.05 | -0.03 | −66.7% |
| Dec 18, 2024 | -0.04 | -0.03 | −33.3% |
| Aug 13, 2024 | 0.02 | -0.05 | +140.0% |
News
Key deals this week: PANW, META, OGI, CRM and moreSeeking Alpha · Nov 7, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
72Pass
Philip Fisher
41No pass
Peter Lynch
71Pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
35No pass
Questions about Organigram Global
Is Organigram Global a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Organigram Global AI analysis
What does Organigram Global do?
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It is in Drug Manufacturers - Specialty & Generic.
Does Organigram Global pay a dividend?
No. Organigram Global does not pay a dividend at the moment.
Is Organigram Global stock halal?
No. Organigram Global does not pass our halal screen: its cash and receivables are 56% of its market value, at or above the 49% limit. How we check
How has Organigram Global stock done over the past year?
Down 48.2% over the past twelve months, to $0.83. It traded between $0.83 and $2.11 and is 60.5% below its high.
Who are Organigram Global's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Organigram Global's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.